The interplay between Epstein-Barr virus and B lymphocytes: Implications for infection, immunity, and disease

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 268-276

  Hatton, Olivia L ^a   Harris Arnold, Aleishia ^a   Schaffert, Steven ^a   Krams, Sheri M ^a   Martinez, Olivia M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; Epstein Barr virus; Latent membrane protein 1; microRNA; Signal transduction

Indexed keywords

LATENT MEMBRANE PROTEIN 1; MICRORNA; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; ONCOPROTEIN;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MEMORY CELL; MONONUCLEOSIS; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS PARTICLE; EPSTEIN BARR VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY;

B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; MICRORNAS; ONCOGENE PROTEINS, VIRAL; VIRAL MATRIX PROTEINS;

EID: 84901603115     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8496-1     Document Type: Article

References (68)

1. Shannon-Lowe C, Rowe M. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog. 2011;7(5):e1001338 (Epub 2011/05/17).
2. Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, et al. Epstein-Barr virus infection of naive B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology. PLoS Pathog. 2012;8(5):e1002697 (Epub 2012/05/17).
3. Kurth J, Spieker T, Wustrow J, Strickler GJ, Hansmann LM, Rajewsky K, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 2000;13(4):485-95 (Epub 2000/11/09).
4. Tracy SI, Kakalacheva K, Lunemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson DA. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol. 2012;86(22):12330-40 (Epub 2012/09/07).
5. Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, et al. Increased CD8 + T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220 (Epub 2013/04/18).
6. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
7. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, et al. Direct visualization of antigen-specific CD8 + T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998;187(9):1395-402. (Pubitemid 28215399)
8. Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, et al. MHC II tetramers visualize human CD4 + T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med. 2013;210(5):933-49 (Epub 2013/04/10).
9. Falco DA, Nepomuceno RR, Krams SM, Lee PP, Davis MM, Salvatierra O, et al. Identification of Epstein-Barr virus-specific CD8 + T lymphocytes in the circulation of pediatric transplant recipients. Transplantation. 2002;74(4):501-10 Epub 2002/09/28.
10. Macedo C, Webber SA, Donnenberg AD, Popescu I, Hua Y, Green M, et al. EBV-specific CD8 + T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J Immunol. 2011;186(10):5854-62 Epub 2011/04/05.
11. Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, Harrison N, et al. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol. 2005;129(2):266-74 Epub 2005/04/09.
12. Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V, et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 2013;5(6):1489-98 Epub 2013/12/24.
13. Lunemann A, Vanoaica LD, Azzi T, Nadal D, Munz C. A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J Immunol. 2013;191(10):4989-95 Epub 2013/10/11.
14. Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. Mg2 + regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341(6142):186-91 Epub 2013/07/13.
15. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virusinfected cells. J Exp Med. 2000;192(3):337-46 Epub 2000/08/10.
16. Eidenschenk C, Dunne J, Jouanguy E, Fourlinnie C, Gineau L, Bacq D, et al. A novel primary immunodeficiency with specific naturalkiller cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet. 2006;78(4):721-7 Epub 2006/03/15.
17. Shaw RK, Issekutz AC, Fraser R, Schmit P, Morash B, Monaco-Shawver L, et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood. 2012;119(17):4009-12 Epub 2012/03/20.
18. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transpl. 2007;7(2):271-7. (Pubitemid 46096319)
19. Ning S. Innate immune modulation in EBV infection. Herpesviridae. 2011;2(1):1 (Epub 2011/03/25).
20. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol. 2008;18(6):397-408 Epub 2008/11/04.
21. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog. 2012;8(5):e1002704 (Epub 2012/05/23).
22. Cohen JI, Lekstrom K. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol. 1999;73(9):7627-32 (Epub 1999/08/10).
23. Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, Burrows SR, et al. Endogenous presentation of CD8 + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med. 2004;199(10):1421-31 (Epub 2004/05/19).
24. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8 + T lymphocytes. J Exp Med. 2004;199(4):459-70 (Epub 2004/02/11).
25. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, et al. A CD8 + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in old world primates. J Exp Med. 2007;204(8):1863-73 (Epub 2007/07/11).
26. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, Ressing ME, et al. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8 + T cells through an additional host shutoff function. J Virol. 2008;82(5):2385-93. (Pubitemid 351293539)
27. Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009;5(1):e1000255 (Epub 2009/01/03).
28. Desbien AL, Kappler JW, Marrack P. The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim. Proc Natl Acad Sci U S A. 2009;106(14):5663-8 Epub 2009/03/19.
29. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol. 2001;167(9):5404-11 Epub 2001/10/24.
30. Snow AL, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006;177(5):3283-93 Epub 2006/08/22.
31. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992;267(34):24157-60.
32. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65(7):1107-15. (Pubitemid 121001325)
33. Wang S, Rowe M, Lundgren E. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res. 1996;56(20):4610-3. (Pubitemid 26338058)
34. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, Lee TH. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem. 2000;275(24):18022-8. (Pubitemid 30414748)
35. Kaye K, Izumi KM, Kieff E. Epstein Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90:9150-4. (Pubitemid 23306469)
36. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43(3 Pt 2):831-40.
37. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol. 1997;158(9):4045-51 (Epub 1997/05/01).
38. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation. 1995;59(4):519-24 (Epub 1995/02/27).
39. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63(15):4472-80 (Epub 2003/08/09).
40. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-41 (Epub 2012/01/10).
41. Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol. 2007;179(12):8225-34.
42. Hatton O, Lambert SL, Krams SM, Martinez OM. Src kinase and Syk activation initiate PI3 K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV) + B cell lymphomas. PLoS ONE. 2012;7(8):e42610.
43. Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus + (EBV +) B cell lymphomas. J Biol Chem. 2011;286(43):37368- 78 (Epub 2011/09/13).
44. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cellcycle protein expression. Transplantation. 2007;83(8):1114-21. (Pubitemid 46659124)
45. Furukawa S, Wei L, Krams SM, Esquivel CO, Martinez OM. PI3 K delta inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV) + B cell lymphomas. Am J Transpl. 2013;13(8):2035-43 (Epub 2013/07/12).
46. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science. 2004;304(5671):734-6. (Pubitemid 38560879)
47. Kincaid RP, Sullivan CS. Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog. 2012;8(12):e1003018 (Epub 2013/01/12).
48. Harris A, Krams SM, Martinez OM. MicroRNAs as immune regulators: implications for transplantation. Am J Transpl. 2010;10(4):713-9 (Epub 2010/03/05).
49. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604-8 Epub 2007/04/28.
50. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627-32 (Epub 2005/03/02).
51. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-9 Epub 2005/07/26.
52. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-9 Epub 2006/04/28.
53. Thapa DR, Bhatia K, Bream JH, D'Souza G, Rinaldo CR, Wolinsky S, et al. B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDSrelated non-Hodgkin lymphomas. AIDS. 2012;26(9):1177-80 Epub 2012/04/11.
54. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, et al. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res. 2004;64(21):7655-60 (Epub 2004/11/03).
55. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467(7311):86-90 Epub 2010/08/10.
56. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 2012;8(1):e1002484 (Epub 2012/02/01).
57. Vaysberg M, Hatton O, Lambert SL, Snow AL, Wong B, Krams SM, et al. Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J Biol Chem. 2008;283(52):36573-85 Epub 2008/11/07.
58. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene. 1992;7(11):2131-40 Epub 1992/11/01.
59. Li SN, Chang YS, Liu ST. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene. 1996;12(10):2129-35 Epub 1996/05/16.
60. Johnson RJ, Stack M, Hazlewood SA, Jones M, Blackmore CG, Hu LF, et al. The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol. 1998;72(5):4038-48. (Pubitemid 28188708)
61. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009;143(2):209-21 (Epub 2009/07/15).
62. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol. 2006;80(13):6458-68. (Pubitemid 43927448)
63. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, Webster-Cyriaque J. The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis. 1999;179(4):763-74 Epub 1999/03/09.
64. Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RL, Andresen BS, et al. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood. 1997;90(1):323-30. (Pubitemid 27276577)
65. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr virus infections in healthy individuals. J Virol. 2003;77(11):6546-50 Epub 2003/05/14.
66. Pai S, O'Sullivan B, Abdul-Jabbar I, Peng J, Connoly G, Khanna R, et al. Nasopharyngeal carcinoma-associated Epstein-Barr virus-encoded oncogene latent membrane protein 1 potentiates regulatory T-cell function. Immunol Cell Biol. 2007;85(5):370-7 (Epub 2007/03/21).
67. Lin HJ, Cherng JM, Hung MS, Sayion Y, Lin JC. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. J Biomed Sci. 2005; 12(6):925-36 Epub 2005/11/25.
68. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984;310(5974):207-11 Epub 1984/07/19.